Call Start: 16:30 January 1, 0000 5:07 PM ET
Caladrius Biosciences, Inc. (CLBS)
Q1 2022 Earnings Conference Call
May 5, 2022 16:30 ET
Company Participants
John Menditto - Vice President of Investor Relations & Corporate Communications
David Mazzo - President & Chief Executive Officer
James Nisco - Vice President of Finance & Treasury
Kristen Buck - Chief Medical Officer
Conference Call Participants
Kumar Raja - Brookline Capital Markets
Emanuela Branchetti - H.C. Wainwright
Pete Enderlin - MAZ Partners
Operator
Welcome to the Caladrius Biosciences First Quarter 2022 Financial Results and Business Update Conference Call. Currently, all participants are in origin only mode. Following management's prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today, Thursday, May 5, 2022.
I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead.
John Menditto
Thank you, operator, and good afternoon, everyone. Welcome to Caladrius' First Quarter 2022 Conference Call to discuss our financial results and provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer; Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer; and James Nisco, Vice President of Finance and Treasury. Shortly before this call, we issued a press release announcing our first quarter 2022 financial results, which is available under the Investors and News section of the company's website, along with the webcast replay of this call. If you have not received this news release and you would like to be added to the company's e-mail distribution list, please e-mail me at jmandido@caladrius.com.
Before we begin, I will remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Caladrius. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its forms 10-Q, 8-K and 10-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call remains time sensitive, but contains time-sensitive information that is accurate only as of the date of this broadcast, Thursday, May 5, 2022. Caladrius Bioscience undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.